Authors' objectives:

To summarise the effectiveness and cost-effectiveness of the use of antileukotrienes in the treatment of asthma.

Authors' results and conclusions: Based on current evidence, antileukotrienes (ALTs) have a role in maintenance therapy in some mild to moderate asthmatics. However, long-term and comparative studies [i.e. versus inhaled corticosteroids (ICSs)] have yet to be published, and the role of ALTs as first line therapy or in severe asthma is unknown. The benefits of these agents in terms of their impact on symptoms and pulmonary function are consistent; however, their impact on the use of inhaled corticosteroids or beta-agonists is still not known. Adverse events have been reported. Long term monitoring of patients (an additional cost), will be required to determine the safety of these drugs. Oral formulations may contribute to improved compliance and drug delivery (and, thus, efficacy); but only limited (short-term) information is available for children, where this route would be particularly advantageous.

Authors' recommendations: Based on current evidence, antileukotrienes (ALTs) have a role in maintenance therapy in some mild to moderate asthmatics.

Authors' methods: Summary

Project Status: Completed

URL for project: https://www.ccohta.ca/

Year Published: 1998

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Canada

Organisation Name: Canadian Coordinating Office for Health Technology Assessment

Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;

Contact Name: requests@cadth.ca

Contact Email: requests@cadth.ca

Copyright: Canadian Coordinating Office for Health Technology Assessment, 1998